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Implantable cardioverter-deﬁbrillators (ICDs) have become a
life-saving adjunct treatment over the past 2 decades for
preventing sudden cardiac death (SCD) due to ventricular
arrhythmias.1 Despite the proven clinical beneﬁt of ICDs in
preventing SCD in various clinical trials, endovascular lead-
related complications and inappropriate therapy remain a
challenge. The subcutaneous ICD (S-ICD) system (Boston
Scientiﬁc, Marlborough, MA) offers an effective alternative
treatment option in a select cohort of high-risk patients.2
Inappropriate ICD shocks (IASs) contribute to adverse
outcomes in patients with ICD, and therefore, device
technology has been upgraded over the years to include
rate-, duration-, and stability-based algorithms that prevent
such events. Although the S-ICD demonstrated a greater
speciﬁcity in discriminating supraventricular from ventricu-
lar tachycardia in the Subcutaneous versus Transvenous
Arrhythmia Recognition Testing (START) study, the rate of
IASs in various studies ranges between 5% and 25%.3,4 T-
wave oversensing (TWOS), low amplitude sensing, and
supraventricular arrhythmia above the discrimination zone
were the most commonly reported reasons in various studies
including the EFFORTLESS registry and IDE study.2,5 The
incidence of IASs can be reduced by preprocedural screening
(particularly in young patients with hypertrophic cardiomy-
opathy [HCM]), appropriate vector selection (alternate
vector being a predictor of oversensing), exercise testing,
and dual-zone programming.6–8
While IASs due to low amplitude R waves with position
change in patients programmed to the alternate vector hasKEYWORDS Subcutaneous ICD; Inappropriate shocks; R-wave amplitude;
Amplitude variation; Oversensing; QRS-T ratio; S-ICD screening; Implantable
deﬁbrillators; Slew rate; signal classiﬁcation; baseline shift
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).been described before, ICD discharge due to an increase in R-
wave amplitude and a shift in baseline has not previously been
reported in the current EMBLEM S-ICD (Boston Scientiﬁc,
Marlborough, MA).9
Case report
A 23-year-old female patient with a family history of
cardiomyopathy and positive genetic testing for TNNT gene
mutation received a Boston Scientiﬁc A209 EMBLEM S-
ICD 4 weeks postpartum. She previously had a transvenous
ICD with a Medtronic Sprint Fidelis lead placed at the age of
13. A pediatric cardiologist had recommended device place-
ment after positive genetic screening of the patient and the
demise of her father and a sibling due to sudden cardiac
arrest. This device had reached elective replacement indica-
tor during the last trimester of her pregnancy and almost
concurrently developed high ICD pace-sense lead impe-
dance suggestive of impending lead fracture. Given the
patient’s age, prior endovascular lead-related complications,
unwillingness to proceed with lead extraction, and reported
history of “appropriate” ICD shocks by her mother, she was
considered a suitable candidate for S-ICD implantation. Her
baseline laboratory data were within normal limits, and an
echocardiogram showed normal left ventricular ejection
fraction and no hypertrophy. An electrocardiogram (ECG)
at baseline showed sinus rhythm and a narrow QRS complex
with nonspeciﬁc ST-segment depression. Device implanta-
tion was performed after the patient passed standard ECG
screening algorithm in two vectors in both supine and
standing positions. The baseline R-wave amplitude was
large but within acceptable limits, and the device sensing
vector was set to primary vector by the automatic algorithm.
In addition, 2 zones were programmed with a shock zone at
240 beats/min and a conditional zone at 200 beats/min.
The patient presented with multiple ICD shocks 2 weeks
later while she was walking. None of the episodes were
preceded by anticipated symptoms. She had no evidence of
ventricular arrhythmia upon device interrogation. Her QRSpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Recognize the importance of thorough
preimplantation screening and device
programming in patients with hypertrophic
cardiomyopathy to minimize the risk of
inappropriate therapy.
 Understand the limitations to the use of the
subcutaneous implantable cardioverter-
deﬁbrillator pertaining to its function when
presented with baseline electrocardiographic
abnormalities, particularly R- and T-wave
amplitude variations in genotype-positive young
patients with or without manifest cardiomyopathy.
 Using alternative algorithms and device
programming to address T-wave oversensing in
patients with increased R-wave amplitude and
baseline QRS-T-wave abnormalities until device
technology is upgraded.
Heart Rhythm Case Reports, Vol 0, No 0, Month 20162amplitude was noted to have increased since the implanta-
tion, exceeding the preset device sensing algorithm. This led
to a shift in the baseline and predisposed the patient to double
counting and oversensing (Figure 1). The device was
reprogrammed to the alternate vector with smallest ampli-
tude QRS (Figure 2), and device function was conﬁrmed in
different positions as well as with exercise. No further
oversensing has been recorded since reprogramming.
Discussion
We report a case of inappropriate shocks in a patient with S-
ICD due to a rare cause of oversensing and signal classi-
ﬁcation. R-wave amplitude variation is a known entity,
particularly in younger patients, with age and exercise. Prior
clinical reports and registry data suggest that IASs with
TWOS is observed more commonly with exercise, alternate
vector setting, low amplitude R waves, and posture-related
R-wave amplitude change.9–11 To prevent signal and noise
oversensing of subcutaneous ECG signals, the S-ICD is
equipped with a sensing algorithm threshold that adapts to R-
wave amplitude and decays over time. In addition, cardiac
signals are run through 4 double-detection algorithms that
correlate similarity between stored template at rest and
tachycardia beats, current and previous tachycardia beats
(beat-to-beat polymorphic variation), QRS width compared
to the baseline (beat-to-beat monomorphic relationship), and
correlation of the existing complex to previous com-
plexes.3,12 There are previously reported cases of inappro-
priate ICD discharge occurring with low amplitude R waves,
resulting in rapid decay of sensing threshold and oversensing
of non-QRS physiological signals.9
To our knowledge however, there have been no prior
reports in the EMBLEM series devices of an increase in R-
wave amplitude leading to inappropriate signal classiﬁcation.To date, a small number of such events (o10 of the 17,000 S-
ICD implants) have been reported correlating with a rate of
0.06% on a per device basis (reported based on personal
communication with Boston Scientiﬁc)13. The potential to
introduce errors of this nature during signal classiﬁcation is
more likely when the device attempts to digitalize analog
signals of amplitudes larger than the maximum range of the
S-ICD system.
The S-ICD system is designed to accommodate R-wave
amplitudes that exceed 3 times the typical peak amplitudes
of 1.0 mV. The system analyzes the analog input signal
slew rate (in mV/ms) before its digital conversion. The slew
rate limit deﬁned in the S-ICD system is based on cardiac
signals whereby amplitude changes between baseline and the
maximum allowed amplitude (4.0 mV) of the S-ICD
system change rapidly (eg, within a few milliseconds, 10
ms). In this case, a baseline offset was introduced as the rapid
amplitude change exceeded the slew rate design limit.
Furthermore, the ECG used for sensing is rectiﬁed before
detection, thereby converting it into all positive signals above
the “zero” baseline. A QRS-T ratio of Z3.5 is recommended
to decrease the likelihood of oversensing. However, a shift in
baseline from zero to nonzero value results in the reduction of
the QRS-T with subsequent overcounting and IASs (Figure 3).
After shock delivery, the threshold is reset to that originally
programmed. Using the characteristics of the ECGs (high QRS
amplitude, high slew rates, and elevated heart rates) from these
episodes, nonzero baseline along with oversensing was
successfully reproduced with internal testing. An engineering
design limitation to accommodate high slew rates especially at
elevated heart rates was identiﬁed as the most likely root cause
(Figure 4).
Since this patient had been screened with a standard ECG
algorithm and the alternate vector was available for selection,
the device was reprogrammed. Device function was tested
after reprogramming in multiple positions and with exercise.
No further events have been recorded to date.
The current guidelines recommend against the placement
of a primary prevention ICD in genotype-positive patients
with HCM in the absence of left ventricular hypertrophy or
high-risk features based on potential harm of the procedure
and long-term risk of device-related complications. Recent
registry data have identiﬁed patients with HCM as the cohort
particularly susceptible to IASs due to TWOS. Given the
multiple ECG abnormalities including high R- or T-wave
amplitude, presence of T-wave inversion in 42 leads,
and ST-segment depression, a higher percentage of these
patients maybe ineligible for S-ICD than previously
reported.8,10 It is also important to note that a number of
these patients are young, more likely to achieve higher heart
rate with activity, exhibit R-wave amplitude variation, and
will carry the device for a long period given the overall good
prognosis. A subset of these patients will, however, develop
progressive left ventricular dysfunction and correlate
changes in ECG with the possibility of device failure. This
is also the population that is at higher risk of having
malignant ventricular arrhythmia. Although our patient did
Figure 1 Subcutaneous implantable cardioverter-deﬁbrillator interrogation strip displaying patient in sinus tachycardia. Overcounting and inappropriate
therapy resulted from signal rectiﬁcation in the presence of tall R waves and shift in baseline.
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Figure 2 Alternate vector selection with lowest amplitude R wave.
Heart Rhythm Case Reports, Vol 0, No 0, Month 20164have baseline T-wave abnormalities in more than 2 leads, she
had passed the initial screening in 2 vectors and positions
before implantation.
Suggested solutions for addressing TWOS in patients
with cardiomyopathies particularly HCM is screening with a
disease-speciﬁc preimplantation algorithm, such as addition
of 2.5 mm/mV gain and selection of alternate vector in select
cases. Although off-label, some operators also choose toShock Zone Set at 240 BPM
Condional Zone Set at 200 BPM
Figure 3 Baseline offset with high QRS amplitude decreased the QRS/T
electrocardiogram. © Boston Scientiﬁc, published with permission.implant the lead on the right side of the sternum instead of
left if it allows for a more suitable R-wave amplitude. The
new SMARTPASS feature, which is included in the latest
EMBLEM S-ICD software update, has been observed with
bench testing data to reduce the likelihood of oversensing
caused by transient large R-wave amplitude variation. The
update is expected to reduce the risk of this unusual clinical
problem.Esmated Heart Rate by Device
Episode End Threshold at 176 bpm/ 340 ms
(Condional Zone 300 ms + Hystersis 40 ms)
-wave ratio and an increased predisposition to oversensing. ECG ¼
Shock Zone Set at 240 BPM
CondionalZone Set at 200 BPM
Episode End Threshold at 176 BPM 
Figure 4 Recreated oversensing event with nonzero baseline, high QRS amplitude, and slew rates during internal testing. © Boston Scientiﬁc, published with
permission.
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S-ICDs have become a popular alternative therapy to prevent
SCD particularly in younger patients with cardiomyopathy
who do not require pacing. There are still limitations to the
widespread use of this device pertaining to its function when
presented with baseline ECG abnormalities, R- and T-wave
amplitude variations in particular. Future device technology
and software upgrades are expected to counteract these
problems.
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